01—Abstract
Summary
Summary of the 10-Q filed August 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. (TMO) reported its second-quarter and first-half 2024 results, demonstrating resilience amidst a moderating macroeconomic environment.
Total revenues saw a slight decline year-over-year for both periods, primarily due to a decrease in COVID-19 related product demand. However, the company continues to show strong operational execution with an increase in GAAP operating income and margin, driven by productivity improvements and a favorable business mix, partially offset by lower restructuring charges compared to the prior year. Adjusted operating income and margin remained stable, highlighting the company's consistent performance.
The company also announced the significant acquisition of Olink Holding AB, a move aimed at bolstering its Life Sciences Solutions segment in the high-growth proteomics market. This strategic acquisition, along with ongoing focus on innovation and customer partnerships, positions Thermo Fisher for future growth. Despite the revenue headwinds from declining COVID-19 related sales, the company's strong cash flow generation and robust balance sheet provide confidence in its ability to navigate current market conditions and pursue strategic growth initiatives.
02—Key points
Key Highlights
- Total revenues for the three months ended June 29, 2024, were $10.54 billion, a 1% decrease from the prior year's $10.69 billion, with six-month revenues at $20.89 billion, down 2% from $21.40 billion.
- GAAP operating income increased by 15% to $1.82 billion for the quarter and by 11% to $3.48 billion for the six months, demonstrating strong operational leverage.
- GAAP diluted earnings per share (EPS) rose 15% to $4.04 for the quarter and 10% to $7.50 for the six months, reflecting improved profitability.
- The company successfully acquired Olink Holding AB for $3.21 billion, enhancing its capabilities in the rapidly growing proteomics market within the Life Sciences Solutions segment.
- Free cash flow remained strong, with $2.58 billion generated in the first six months of 2024, up from $1.54 billion in the same period last year.
- The company repurchased $3.00 billion of common stock in the first six months of 2024 and maintained a $1.00 billion authorization for future repurchases.
- Revenue growth was negatively impacted by declining demand for COVID-19 related products and services across multiple segments.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 2, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $10.54B$10.71B | −1.6% |
| R&D Expenses | $339.00M$346.00M | −2.0% |
| SG&A Expenses | $2.11B$2.12B | −0.4% |
| Operating Expenses | $8.72B$9.15B | −4.6% |
| Operating Income | $1.82B$1.56B | +16.4% |
| Net Income | $1.55B$1.29B | +20.5% |
| EPS (Basic) | $4.05$3.34 | +21.3% |
| EPS (Diluted) | $4.04$3.32 | +21.7% |
| Shares Outstanding (Basic) | 382.00M386.00M | −1.0% |
| Shares Outstanding (Diluted) | 383.00M388.00M | −1.3% |
05—Questions
Frequently Asked Questions
What was the impact of the Olink acquisition on Thermo Fisher's financial statements?
The acquisition of Olink Holding AB was completed on July 10, 2024, shortly after the reporting period ended. The preliminary purchase price was $3.21 billion, consisting of $3.19 billion in cash and $0.06 billion in fair value of noncontrolling interest. The acquisition is expected to enhance Thermo Fisher's Life Sciences Solutions segment by adding differentiated proteomics solutions, complementing existing offerings and accelerating protein biomarker discovery. The goodwill recorded from this acquisition is not expected to be tax-deductible.
How did COVID-19 related sales affect Thermo Fisher's revenue?
The decline in demand for products and services supporting COVID-19 vaccines and therapies significantly impacted Thermo Fisher's revenue. Sales of products related to COVID-19 testing were $0.02 billion in Q2 2024, down from $0.08 billion in Q2 2023. For the first six months, these sales were $0.05 billion in 2024, down from $0.22 billion in 2023. This moderation in COVID-19 related demand was a primary driver for the overall revenue decline across several segments.
What is the company's outlook on liquidity and capital resources?
Thermo Fisher Scientific expects its existing cash and cash equivalents, along with future cash flow from operations and available borrowing capacity under its revolving credit facility, to be sufficient to meet its cash requirements for at least the next 24 months. The company generated $3.21 billion in net cash from operating activities in the first six months of 2024. Its primary uses of capital are mergers and acquisitions, followed by share buybacks and dividends.
What are the key drivers behind the increase in GAAP operating income and EPS?
The increase in GAAP operating income and EPS is primarily attributed to strong productivity improvements, including benefits from the company's Practical Process Improvement (PPI) business system, global sourcing, and cost efficiencies from restructuring actions. Additionally, a more favorable business mix and lower levels of restructuring and other charges compared to the prior year also contributed to the improved profitability metrics.
06—Continue